Skip to main content
Erschienen in: European Surgery 2/2015

01.04.2015 | Original Article

Tamoxifen for the prevention of postoperative intra-abdominal adhesions

verfasst von: P. Soleymanzadeh, MD, Assoc. Prof. R. Mirzaei, MD, Prof. B. Mahjoubi, MD, M. Mohammadipour, MD, Prof. D. Sharifi, MD

Erschienen in: European Surgery | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Summary

Background

Postoperative intra-abdominal adhesion (PIAA) is a common complication following abdominal surgeries. Up to now, no practical method or device has been proven to be the gold standard in PIAA formation prevention. This study was designed to evaluate the effects of oral and intraperitoneal tamoxifen citrate on PIAA formation prevention.

Methods

A total of 48 guinea pigs weighing 300–350 g were included in four groups (12 pigs in each group). Under general anesthesia, laparotomy was performed, and a part of small bowel was abraded using wet gauze so that serosal petechiae developed on the intestinal surface for induction of peritoneal adhesion. In group 1 (control), only this adhesion induction was performed with no treatment. In the second group, 2.5 mg/kg/day tamoxifen citrate was administered by orogastric gavage postoperatively. Group 3 underwent adhesion induction and then intraperitoneal administration of 2.5 mg/kg tamoxifen citrate diluted in 10 ml of aquapura. Group 4, underwent adhesion induction and intraperitoneal administration of 2.5 mg/kg tamoxifen citrate diluted in 10 ml aquapura and then 2.5 mg/kg/day tamoxifen citrate was administered by orogastric gavage postoperatively. Pigs underwent laparotomy on the eighth postoperative day, and grading of adhesions was performed according to the Adhesion Characteristic and Adhesion Tenacity scoring system. Data were analyzed using SPSS for Windows version 16.

Results

The control group was significantly different from other groups (p < 0.008), which means usage of tamoxifen (oral or intraperitoneal or both) significantly reduced adhesion formation after laparotomy. Intraperitoneal tamoxifen (group 3) was more effective in prevention of adhesion formation than oral tamoxifen application (group 2; p = 0.006). Also, administration of both oral and intraperitoneal tamoxifen (group 4) reduced adhesions significantly (p = 0.002) in comparison with just oral one (group 2), but it made no difference (p = 0.625) with only intraperitoneal tamoxifen (group 3).

Conclusions

This study indicated that tamoxifen significantly reduces PIAAs, and intraperitoneal application is more effective than oral administration. This study shows that preventive effects of intraperitoneal application of tamoxifen will not improve when oral tamoxifen is added postoperatively. More studies with focus on evaluation of probable side effects and also performing clinical trials for evaluating tamoxifen for preventing PIAAs are strongly suggested.
Literatur
1.
Zurück zum Zitat Yilmaz HG, Tacyildiz I, Keles C, Gedik E, Kilinc N. Micronized purified flavonoid fraction may prevent formation of intraperitoneal adhesions in rats. Fertil Steril. 2005;84(Suppl. 2):1083–88.CrossRefPubMed Yilmaz HG, Tacyildiz I, Keles C, Gedik E, Kilinc N. Micronized purified flavonoid fraction may prevent formation of intraperitoneal adhesions in rats. Fertil Steril. 2005;84(Suppl. 2):1083–88.CrossRefPubMed
2.
Zurück zum Zitat Falabella CA, Melendez MM, Weng L, Chen W. Novel macromolecular crosslinking hydrogel to reduce intra-abdominal adhesions. J Surg Res. 2010;159(2):772–8. PubMed PMID: 19481223. English.CrossRefPubMed Falabella CA, Melendez MM, Weng L, Chen W. Novel macromolecular crosslinking hydrogel to reduce intra-abdominal adhesions. J Surg Res. 2010;159(2):772–8. PubMed PMID: 19481223. English.CrossRefPubMed
3.
Zurück zum Zitat Van Der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, Reijnen MM, Schaapveld M, Van Goor H. Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg. 2000;87(4):467–71. PubMed PMID: 10759744. English.CrossRefPubMed Van Der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, Reijnen MM, Schaapveld M, Van Goor H. Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg. 2000;87(4):467–71. PubMed PMID: 10759744. English.CrossRefPubMed
4.
Zurück zum Zitat Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, et al. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet. 1999;353(9163):1476–80. PubMed PMID: 10232313. English.CrossRefPubMed Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, et al. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet. 1999;353(9163):1476–80. PubMed PMID: 10232313. English.CrossRefPubMed
5.
Zurück zum Zitat Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg. 2001;3(2):111–4.CrossRefPubMed Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg. 2001;3(2):111–4.CrossRefPubMed
6.
Zurück zum Zitat Carmichael PL, Pole JC, Neven P. Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifen. Eur J Cancer. 2000;36(Suppl. 4):S42p3. Carmichael PL, Pole JC, Neven P. Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifen. Eur J Cancer. 2000;36(Suppl. 4):S42p3.
7.
Zurück zum Zitat Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006;56(3):301–5.CrossRefPubMed Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006;56(3):301–5.CrossRefPubMed
8.
Zurück zum Zitat Ryu SH, Chung YH, Lee JK, et al. Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis. Liver Int. 2009;29(2):308–14.CrossRefPubMed Ryu SH, Chung YH, Lee JK, et al. Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis. Liver Int. 2009;29(2):308–14.CrossRefPubMed
9.
Zurück zum Zitat Mohamed AO, Kamar N, Nogier MB, Esposito L, Duffas JP, Rostaing L. Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. Exp Clin Transplant. 2009;7(3):164–7.PubMed Mohamed AO, Kamar N, Nogier MB, Esposito L, Duffas JP, Rostaing L. Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. Exp Clin Transplant. 2009;7(3):164–7.PubMed
10.
Zurück zum Zitat Loureiro J, Sandoval P, del Peso G, Gónzalez-Mateo G, Fernández-Millara V, Santamaria B, Bajo MA, Sánchez-Tomero JA, Guerra-Azcona G, Selgas R, López-Cabrera M, Aguilera AI. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One. 2013;8(4):e61165.CrossRefPubMedCentralPubMed Loureiro J, Sandoval P, del Peso G, Gónzalez-Mateo G, Fernández-Millara V, Santamaria B, Bajo MA, Sánchez-Tomero JA, Guerra-Azcona G, Selgas R, López-Cabrera M, Aguilera AI. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One. 2013;8(4):e61165.CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Frankart L, Lorge F, Donckier J. Tamoxifen for retroperitoneal fibrosis. Postgrad Med J. 1997;73(864):653–4. Frankart L, Lorge F, Donckier J. Tamoxifen for retroperitoneal fibrosis. Postgrad Med J. 1997;73(864):653–4.
12.
Zurück zum Zitat Tallarigo C, D’Amico A, Porcaro AB, et al. Our experience in the treatment of retroperitoneal fibrosis. Arch Ital Urol Androl. 2000;72(2):51–8.PubMed Tallarigo C, D’Amico A, Porcaro AB, et al. Our experience in the treatment of retroperitoneal fibrosis. Arch Ital Urol Androl. 2000;72(2):51–8.PubMed
13.
Zurück zum Zitat Dedeoglu F, Rose CD, Athreya BH, et al. Successful treatment of retroperitoneal fibrosis with tamoxifen in a child. J Rheumatol. 2001;28(7):1693–5. Dedeoglu F, Rose CD, Athreya BH, et al. Successful treatment of retroperitoneal fibrosis with tamoxifen in a child. J Rheumatol. 2001;28(7):1693–5.
14.
Zurück zum Zitat Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005;68(5):2381–8.CrossRefPubMed Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005;68(5):2381–8.CrossRefPubMed
15.
Zurück zum Zitat del Peso G, Bajo MA, Gil F, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial. 2003;19:32–5.PubMed del Peso G, Bajo MA, Gil F, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial. 2003;19:32–5.PubMed
16.
Zurück zum Zitat Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol. 1999;12(6):395–7.PubMed Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol. 1999;12(6):395–7.PubMed
17.
Zurück zum Zitat Moustafellos P, Hadjianastassiou V, Roy D, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc. 2006;38(9):2913–4.CrossRefPubMed Moustafellos P, Hadjianastassiou V, Roy D, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc. 2006;38(9):2913–4.CrossRefPubMed
18.
Zurück zum Zitat Karaca T, Gozalan AU, Yoldas O, Bilgin BC, Tezer A. Effects of tamoxifen citrate on postoperative intra-abdominal adhesion in a rat model. Int J Surg. 2013;11(1):68–72. PubMed PMID: 23211136. English.CrossRefPubMed Karaca T, Gozalan AU, Yoldas O, Bilgin BC, Tezer A. Effects of tamoxifen citrate on postoperative intra-abdominal adhesion in a rat model. Int J Surg. 2013;11(1):68–72. PubMed PMID: 23211136. English.CrossRefPubMed
19.
Zurück zum Zitat Emre A, Akin M, Isikgonul I, Yuksel O, Anadol AZ, Cifter C. Comparison of intraperitoneal honey and sodium hyaluronate-carboxymethylcellulose (Seprafilm) for the prevention of postoperative intra-abdominal adhesions. Clinics (Sao Paulo). 2009;64(4):363–8. PubMed PMID: 19488596. PubMed Central PMCID: 2694453. English.CrossRef Emre A, Akin M, Isikgonul I, Yuksel O, Anadol AZ, Cifter C. Comparison of intraperitoneal honey and sodium hyaluronate-carboxymethylcellulose (Seprafilm) for the prevention of postoperative intra-abdominal adhesions. Clinics (Sao Paulo). 2009;64(4):363–8. PubMed PMID: 19488596. PubMed Central PMCID: 2694453. English.CrossRef
20.
Zurück zum Zitat Gomel V, Urman B, Gurgan T. Pathophysiology of adhesion formation and strategies for prevention. J Reprod Med. 1996;41:35–41.PubMed Gomel V, Urman B, Gurgan T. Pathophysiology of adhesion formation and strategies for prevention. J Reprod Med. 1996;41:35–41.PubMed
21.
Zurück zum Zitat Linsky CB, Diamond M, Cunningham T, Constantine B, DeCherney AH, diZerega GS. Adhesion reduction in the rabbit uterine horn model using an absorbable barrier, TC-7. J Reprod Med. 1987;32(1):17–20.PubMed Linsky CB, Diamond M, Cunningham T, Constantine B, DeCherney AH, diZerega GS. Adhesion reduction in the rabbit uterine horn model using an absorbable barrier, TC-7. J Reprod Med. 1987;32(1):17–20.PubMed
22.
Zurück zum Zitat Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H. Effect of polylactic acid film barrier on intra-abdominal adhesion formation. J Surg Res. 2008;147(1):148–52. PubMed PMID: 18262551. English.CrossRefPubMed Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H. Effect of polylactic acid film barrier on intra-abdominal adhesion formation. J Surg Res. 2008;147(1):148–52. PubMed PMID: 18262551. English.CrossRefPubMed
23.
Zurück zum Zitat Shih S-C, Jeng K-S, Lin SC, Kao C-R, Chou S-Y, Wang H-Y, Chang W-H, Chu C-H, Wang T-E. Adhesive small bowel obstruction: how long can patients tolerate conservative treatment? World J Gastroenterol. 2003;9(3):603–5.PubMed Shih S-C, Jeng K-S, Lin SC, Kao C-R, Chou S-Y, Wang H-Y, Chang W-H, Chu C-H, Wang T-E. Adhesive small bowel obstruction: how long can patients tolerate conservative treatment? World J Gastroenterol. 2003;9(3):603–5.PubMed
24.
Zurück zum Zitat Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, et al. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum. 2005;48(6):1130–9. PubMed PMID: 15868230. English.CrossRefPubMed Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, et al. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum. 2005;48(6):1130–9. PubMed PMID: 15868230. English.CrossRefPubMed
25.
Zurück zum Zitat Sulaiman H, Gabella G, Davis MC, Mutsaers SE, Boulos P, Laurent GJ, et al. Presence and distribution of sensory nerve fibers in human peritoneal adhesions. Ann Surg. 2001;234(2):256–61. PubMed PMID: 11505072. PubMed Central PMCID: 1422013. English.CrossRefPubMedCentralPubMed Sulaiman H, Gabella G, Davis MC, Mutsaers SE, Boulos P, Laurent GJ, et al. Presence and distribution of sensory nerve fibers in human peritoneal adhesions. Ann Surg. 2001;234(2):256–61. PubMed PMID: 11505072. PubMed Central PMCID: 1422013. English.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Becker JM, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, et al. Prevention postoperative abdominal adhesion by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized double-blind multicenter study. J Am Coll Surg. 1996;183:297–306.PubMed Becker JM, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, et al. Prevention postoperative abdominal adhesion by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized double-blind multicenter study. J Am Coll Surg. 1996;183:297–306.PubMed
27.
Zurück zum Zitat Arikan S, Adas G, Barut G, Toklu AS, Kocakusak A, Uzun H, et al. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing. Am J Surg. 2005;189:155–60.CrossRefPubMed Arikan S, Adas G, Barut G, Toklu AS, Kocakusak A, Uzun H, et al. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing. Am J Surg. 2005;189:155–60.CrossRefPubMed
28.
Zurück zum Zitat Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, 2nd, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate/carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol. 2007;104:739–46.CrossRefPubMed Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, 2nd, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate/carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol. 2007;104:739–46.CrossRefPubMed
29.
Zurück zum Zitat Schindler AE. Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. Gynecol Endocrinol. 2004;19(1):51–5. PubMed PMID: 15625774. English.CrossRefPubMed Schindler AE. Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. Gynecol Endocrinol. 2004;19(1):51–5. PubMed PMID: 15625774. English.CrossRefPubMed
30.
Zurück zum Zitat Tarhan OR, Barut I, Sezik M. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. J Surg Res. 2008;144(1):151–7. PubMed PMID: 17981298. English.CrossRefPubMed Tarhan OR, Barut I, Sezik M. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. J Surg Res. 2008;144(1):151–7. PubMed PMID: 17981298. English.CrossRefPubMed
31.
Zurück zum Zitat Yeo Y, Kohane DS. Polymers in the prevention of peritoneal adhesions. Eur J Pharm Biopharm. 2008;68:5708t. Yeo Y, Kohane DS. Polymers in the prevention of peritoneal adhesions. Eur J Pharm Biopharm. 2008;68:5708t.
32.
Zurück zum Zitat Cheung JP, Tsang HH, Cheung JJ, Yu HH, Leung GK, Law WL. Adjuvant therapy for the reduction of postoperative intra-abdominal adhesion formation. Asian J Surg. 2009;32(3):180–6. PubMed PMID: 19656760. English.CrossRefPubMed Cheung JP, Tsang HH, Cheung JJ, Yu HH, Leung GK, Law WL. Adjuvant therapy for the reduction of postoperative intra-abdominal adhesion formation. Asian J Surg. 2009;32(3):180–6. PubMed PMID: 19656760. English.CrossRefPubMed
33.
Zurück zum Zitat Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW. Comparison of a novel liquid (Adcon-P) and a sodium hyaluronate and carboxymethylcellulose membrane (Seprafilm) in postsurgical adhesion formation in a murine model. Dis Colon Rectum. 2003;46(2):187–91. PubMed PMID: 12576892. English.CrossRefPubMed Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW. Comparison of a novel liquid (Adcon-P) and a sodium hyaluronate and carboxymethylcellulose membrane (Seprafilm) in postsurgical adhesion formation in a murine model. Dis Colon Rectum. 2003;46(2):187–91. PubMed PMID: 12576892. English.CrossRefPubMed
34.
Zurück zum Zitat Altuntas I, Tarhan O, Delibas N. Seprafilm reduces adhesions to polypropylene mesh and increases peritoneal hydroxyproline. Am Surg. 2002;68(9):759–61. PubMed PMID: 12356144. English.PubMed Altuntas I, Tarhan O, Delibas N. Seprafilm reduces adhesions to polypropylene mesh and increases peritoneal hydroxyproline. Am Surg. 2002;68(9):759–61. PubMed PMID: 12356144. English.PubMed
35.
Zurück zum Zitat Beck DE. The role of Seprafilm bioresorbable membrane in adhesion prevention. Eur J Surg Suppl. 1997;(577):4977J. PubMed PMID: 9076452. English. Beck DE. The role of Seprafilm bioresorbable membrane in adhesion prevention. Eur J Surg Suppl. 1997;(577):4977J. PubMed PMID: 9076452. English.
36.
Zurück zum Zitat Alimoglu O, Akcakaya A, Sahin M, Unlu Y, Ozkan OV, Sanli E, et al. Prevention of adhesion formations following repair of abdominal wall defects with prosthetic materials (an experimental study). Hepatogastroenterology. 2003;50(51):725–8. PubMed PMID: 12828071. English.PubMed Alimoglu O, Akcakaya A, Sahin M, Unlu Y, Ozkan OV, Sanli E, et al. Prevention of adhesion formations following repair of abdominal wall defects with prosthetic materials (an experimental study). Hepatogastroenterology. 2003;50(51):725–8. PubMed PMID: 12828071. English.PubMed
37.
Zurück zum Zitat Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H. Comparison of the two types of bioresorbable barriers to prevent intra-abdominal adhesions in rats. J Gastrointest Surg. 2009;13(2):282–6. PubMed PMID: 18777122. English.CrossRefPubMed Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H. Comparison of the two types of bioresorbable barriers to prevent intra-abdominal adhesions in rats. J Gastrointest Surg. 2009;13(2):282–6. PubMed PMID: 18777122. English.CrossRefPubMed
38.
Zurück zum Zitat Avital S, Bollinger TJ, Wilkinson JD, Marchetti F, Hellinger MD, Sands LR. Preventing intra-abdominal adhesions with polylactic acid film: an animal study. Dis Colon Rectum. 2005;48(1):153–7. PubMed PMID: 15690673. English.CrossRefPubMed Avital S, Bollinger TJ, Wilkinson JD, Marchetti F, Hellinger MD, Sands LR. Preventing intra-abdominal adhesions with polylactic acid film: an animal study. Dis Colon Rectum. 2005;48(1):153–7. PubMed PMID: 15690673. English.CrossRefPubMed
39.
Zurück zum Zitat Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, et al. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res. 2008;149(1):115–9. PubMed PMID: 18374947. English.CrossRefPubMed Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, et al. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res. 2008;149(1):115–9. PubMed PMID: 18374947. English.CrossRefPubMed
40.
Zurück zum Zitat Hard GC, Iatropoulos MJ, Jordan K. Major difference in the hepatocarcinogenecity and DNA adduct forming ability between toremifene and tamoxifen in female rats. Cancer Res. 1993;53:4534–41.PubMed Hard GC, Iatropoulos MJ, Jordan K. Major difference in the hepatocarcinogenecity and DNA adduct forming ability between toremifene and tamoxifen in female rats. Cancer Res. 1993;53:4534–41.PubMed
41.
Zurück zum Zitat Athoupa M, Hirsimaki P, Parssinen R, Mantyla E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in rats. Carcinogenesis. 1994;15:863–8.CrossRef Athoupa M, Hirsimaki P, Parssinen R, Mantyla E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in rats. Carcinogenesis. 1994;15:863–8.CrossRef
42.
Zurück zum Zitat Karki A, Mantyla E, Hirsimaki Y, Karlsson S, Toikkanen S, Hirsimaki P. Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis. Arch Toxicol. 2000;74:249–56.CrossRefPubMed Karki A, Mantyla E, Hirsimaki Y, Karlsson S, Toikkanen S, Hirsimaki P. Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis. Arch Toxicol. 2000;74:249–56.CrossRefPubMed
43.
Zurück zum Zitat El-Beshbishy H. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective. J Biochem Mol Biol. 2005;38:300–6.CrossRefPubMed El-Beshbishy H. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective. J Biochem Mol Biol. 2005;38:300–6.CrossRefPubMed
44.
Zurück zum Zitat Desai P, Nallani S, Sane R, Moore L, Goodwin B, Buckley D, Buckley A. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:608–12.CrossRefPubMed Desai P, Nallani S, Sane R, Moore L, Goodwin B, Buckley D, Buckley A. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:608–12.CrossRefPubMed
Metadaten
Titel
Tamoxifen for the prevention of postoperative intra-abdominal adhesions
verfasst von
P. Soleymanzadeh, MD
Assoc. Prof. R. Mirzaei, MD
Prof. B. Mahjoubi, MD
M. Mohammadipour, MD
Prof. D. Sharifi, MD
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 2/2015
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-015-0306-z

Weitere Artikel der Ausgabe 2/2015

European Surgery 2/2015 Zur Ausgabe